PPARGC1A and lip and oral cavity carcinoma: Our results confirm the idea that PPARGC1A inhibition enhanced cisplatin-induced mitochondrial dysfunction, which triggers mitochondrial (mt)ROS-dependent apoptosis in oral cancer cells.